Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (271-280 of 308) with videos related to

Pageof 31
Sort By:
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
Annals of Surgical Oncology|August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology|August 29, 2025
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
BMJ Open|June 6, 2022
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operationsDaniel Clark Files, Michael A Matthay, Carolyn S Calfee, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Annals of Surgical Oncology|July 24, 2025
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Annals of Surgical Oncology|July 23, 2025
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 TrialMandeep Kaur, Katrina Dimitroff, Judy C Boughey, et al.
Pageof 31

Showing results (271-280 of 308) with videos related to

Sort By:
Pageof 31
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
Annals of Surgical Oncology|August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology|August 29, 2025
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
BMJ Open|June 6, 2022
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operationsDaniel Clark Files, Michael A Matthay, Carolyn S Calfee, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Annals of Surgical Oncology|July 24, 2025
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Annals of Surgical Oncology|July 23, 2025
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 TrialMandeep Kaur, Katrina Dimitroff, Judy C Boughey, et al.
Pageof 31